Trials / Unknown
UnknownNCT05380882
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
A Phase I Study of TQB2930 Injection in Patients With Advanced Cancers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection in subjects with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2930 injection | TQB2930 is an anti-HER2 bispecific antibody. |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2023-04-01
- Completion
- 2023-12-01
- First posted
- 2022-05-19
- Last updated
- 2022-05-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05380882. Inclusion in this directory is not an endorsement.